igf-1 lr3 with retatrutide (GLP-3) – Y&P Labs Retatrutide And Igf 1 Lr3

Reed, Michael C., et al

Qiu YH, Xu YL, Zhang WH

Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up

At the recommended dosage of one tablet twice daily, each bottle should last for about one month